Biosapien, a biotech company, has successfully raised $7 million in a Pre-Series A funding round with the participation of Golden Gate Ventures, marking their first investment in the region.
This funding follows a $5.5 million round led by Global Ventures in December.
The company plans to use the funding to accelerate clinical trials for its MediChip platform in the UAE, set to begin in Q2 2025, as well as to enhance product development and expand manufacturing capabilities.
MediChip, based on 3D printing technology, offers an innovative solution for delivering drugs directly to cancerous tumors, reducing drug quantities and side effects while maintaining efficacy.
The clinical trials will focus on colorectal cancer patients, with plans to expand to other cancer types and non-cancer therapeutic applications.
Biosapien aims to treat over one million patients by 2035, leveraging the UAE’s support for advanced healthcare initiatives.
